Market Research Logo

Thromboembolism - Pipeline Review, H1 2015

Thromboembolism - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Thromboembolism - Pipeline Review, H1 2015’, provides an overview of the Thromboembolism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thromboembolism
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Thromboembolism and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Thromboembolism
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Thromboembolism Overview
Therapeutics Development
Pipeline Products for Thromboembolism - Overview
Pipeline Products for Thromboembolism - Comparative Analysis
Thromboembolism - Therapeutics under Development by Companies
Thromboembolism - Therapeutics under Investigation by Universities/Institutes
Thromboembolism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Thromboembolism - Products under Development by Companies
Thromboembolism - Products under Investigation by Universities/Institutes
Thromboembolism - Companies Involved in Therapeutics Development
Bayer AG
Cereno Scientific AB
CSL Limited
Daiichi Sankyo Company, Limited
Gamma Therapeutics, Inc.
Green Cross Corporation
Isis Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Regado Biosciences, Inc.
Sanofi
Thromboembolism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
betrixaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSL-3F7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gammarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GCC-2107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-FXIRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lysimab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protein for Thromboembolism and Blood Coagulation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REG-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
semuloparin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit HDAC for Thromboembolism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAP-ANV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YG-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thromboembolism - Recent Pipeline Updates
Thromboembolism - Dormant Projects
Thromboembolism - Discontinued Products
Thromboembolism - Product Development Milestones
Featured News & Press Releases
Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation
Sep 26, 2014: Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA (edoxaban) in Japan
Aug 30, 2014: Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)
Jun 23, 2014: Regado Biosciences REG2 Demonstrates Dose and Concentration Dependent Suppression of Thrombin Generation
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
May 12, 2014: Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Thromboembolism, H1 2015
Number of Products under Development for Thromboembolism - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Thromboembolism - Pipeline by Bayer AG, H1 2015
Thromboembolism - Pipeline by Cereno Scientific AB, H1 2015
Thromboembolism - Pipeline by CSL Limited, H1 2015
Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H1 2015
Thromboembolism - Pipeline by Green Cross Corporation, H1 2015
Thromboembolism - Pipeline by Isis Pharmaceuticals, Inc., H1 2015
Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H1 2015
Thromboembolism - Pipeline by Regado Biosciences, Inc., H1 2015
Thromboembolism - Pipeline by Sanofi, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Thromboembolism Therapeutics - Recent Pipeline Updates, H1 2015
Thromboembolism - Dormant Projects, H1 2015
Thromboembolism - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Thromboembolism, H1 2015
Number of Products under Development for Thromboembolism - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report